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Introduction: Traditional risk scoring prediction models for trauma use either anatomically based estimations of
injury or presenting vital signs. Markers of organ dysfunction may provide additional prognostic capability to these
models. The objective of this study was to evaluate if urinary biomarkers are associated with poor outcomes,
including death and the need for renal replacement therapy.
Methods: We conducted a prospective, observational study in United States Military personnel with traumatic
injury admitted to the intensive care unit at a combat support hospital in Afghanistan.
Results: Eighty nine patients with urine samples drawn at admission to the intensive care unit were studied.
Twelve patients subsequently died or needed renal replacement therapy. Median admission levels of urinary
cystatin C (CyC), interleukin 18 (IL-18), L-type fatty acid binding protein (LFABP) and neutrophil gelatinase-associated
lipocalin (NGAL) were significantly higher in patients that developed the combined outcome of death or need for
renal replacement therapy. Median admission levels of kidney injury molecule-1 were not associated with the
combined outcome. The area under the receiver operating characteristic curves for the combined outcome were
0.815, 0.682, 0.842 and 0.820 for CyC, IL-18, LFABP and NGAL, respectively. Multivariable regression adjusted for
injury severity score, revealed CyC (OR 1.97, 95 % confidence interval 1.26-3.10, p = 0.003), LFABP (OR 1.92, 95 %
confidence interval 1.24-2.99, p = 0.004) and NGAL (OR 1.80, 95 % confidence interval 1.21-2.66, p = 0.004) to be
significantly associated with the composite outcome.
Conclusions: Urinary biomarker levels at the time of admission are associated with death or need for renal
replacement therapy. Larger multicenter studies will be required to determine how urinary biomarkers can best be
used in future prediction models.Introduction
A variety of risk prediction scores, including the injury
severity score (ISS) [1] and the revised trauma score
(RTS) [2], can be used to predict mortality after trau-
matic injury. These models are based on anatomical
injury descriptions (in the case of ISS) and physiologic
parameters to include vital signs and the Glasgow coma* Correspondence: ian.stewart@us.af.mil
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organ dysfunction, such as urinary biomarkers (UBs),
may provide additional information that could be used
to refine these models.
In the care of combat injured patients, risk prediction
is especially important as military physicians have lim-
ited resources and triage decisions must be rapid and ac-
curate. The ability to identify patients who will require a
large amount of resources is paramount, but is a process
currently based on clinical intuition. An objective test is
needed to support the decision making process. Further-
more, studies in combat injured patients represent article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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subjects. This might provide insights into subpopula-
tions of civilian trauma populations and aid in the re-
finement of risk prediction models.
Given the paucity of data on UBs in the setting of
trauma, we sought to determine the potential utility of
UBs in an austere deployed environment to predict poor
outcomes. We hypothesized that UBs would predict a
combined outcome of severe acute kidney injury (AKI),
defined by the need for renal replacement therapy
(RRT), or death.
Methods
The study took place at Craig Joint Theater Hospital
(CJTH) in Bagram Airfield, Afghanistan from October
2012 to December 2013. We included US military
personnel with traumatic injury that required ICU-level
care. Patients were excluded if they did not have a Foley
catheter or if more than 48 hours had elapsed since in-
jury. The study was approved by the institutional review
board responsible for studies performed in theater (the
US Army Medical Research and Materiel Command).
Informed consent was deemed necessary if the subject
was able to provide consent. However, given the inability
to access legally authorized representatives, this require-
ment was waived given the low risk nature of the study
for patients unable to consent.
We collected urine samples within 3 hours of admission
to the ICU. Within 1 hour, samples were centrifuged at
2,000 g for 10 minutes and then frozen at −80 °C. Samples
were batched and shipped back to the United States using
a commercial carrier. A temperature logger was included
in the sample shipment to ensure that the samples
remained at an appropriate temperature (less than −40 °C).
Urinary biomarkers measured included neutrophil gelati-
nase-associated lipocalin (NGAL), cystatin C (CyC), kidney
injury molecule-1 (KIM-1), interleukin (IL)-18, and L-type
fatty acid-binding protein (L-FABP). Results were obtained
using commercially available kits for NGAL (RnD Systems,
Minneapolis, MN, USA), KIM-1 (RnD Systems), IL-18
(MBL International, Woburn, MA, USA), L-FABP (Hycult
Biotech, Plymouth Meeting, PA, USA), and CyC (RnD Sys-
tems). All samples were run twice and the average of these
two values was used for analysis. The results were normal-
ized for urine concentration by dividing by the urinary cre-
atinine concentration.
Data collection was accomplished in both a prospect-
ive and retrospective fashion. Data on demographics, ISS
[1], blood transfusions and laboratory values were col-
lected prospectively by the investigators at CJTH.
Massive transfusion was defined at ≥10 units of packed
red blood cells in a 24 hour period. Data on events that
occurred after patient evacuation from CJTH, to include
the need for RRT at Landstuhl Regional Medical Center(a military hospital in Germany, which is the next step
in the evacuation chain) and in-hospital death were col-
lected retrospectively. Specific criteria to start RRT were
not part of the protocol. Physicians who were not in-
volved in the study determined if the patients needed
RRT. Patients who died at any point during their initial
hospitalization were considered as meeting the mortality
component of the composite outcome.
The combined outcome was defined as a composite of
death or the need for RRT. To examine the differences
in UB concentrations between those that developed the
combined outcome and those that did not we utilized
the Wilcoxon rank sum test. To determine the diagnos-
tic characteristics, we generated receiver operator char-
acteristic (ROC) curves and evaluated the area under the
curves (AUC). We then determined sensitivity, specifi-
city, positive predictive value and negative predictive
value at the point of optimal test performance by deter-
mining the probability cutoff values in which (1) the
overall percent of cases correctly classified > = 70 %, and
(2) sensitivity and specificity both exceeded 60 %, or the
cutoffs as close to these criteria as possible [3]. These
criteria were used as a way to balance the tradeoff be-
tween sensitivity, specificity and overall prediction accur-
acy inherent in the determination of predictive cutoff
values. To see if UBs provided additional information to
that which would possibly be clinically available, we per-
formed logistic regression models with independent vari-
ables of ISS and UBs (normalized for creatinine
concentration) with the dependent variable of the com-
posite outcome. Separate models were run for each of
the five UBs. A two-tailed p value <0.05 was considered
significant. Statistics were performed using SAS version
9.2 (Cary, NC, USA).
Results
Over the course of the study, 126 subjects were admitted
to the ICU at CJTH. Of these, 37 patients were excluded
leaving 89 subjects for analysis. As noted in Fig. 1, pa-
tients were excluded for not having a Foley catheter (21
patients), injury more than 48 hours before admission (7
patients), declined enrollment (4 patients), anuria (2 pa-
tients), urine sample not collected within 3 hours (2 pa-
tients) or withdrawal of consent (1 patient).
The baseline characteristics of study subjects are pre-
sented in Table 1. Average age was 26.9 ± 5.3 years and
the majority (96.6 %) was male. Median (IQR) ISS was
18 (11, 38) denoting severe injury. Median lactate at ad-
mission was 1.8 (1.1, 2.9) mmol/L and 37.1 % of patients
required a massive transfusion. Patients who developed
the composite endpoint were more severely injured as
evidenced by significantly higher ISS and lactates. More
patients who developed the composite endpoint required
a mass transfusion. Six patients (6.7 %) required RRT.
Fig. 1 Cohort derivation
Table 1 Baseline characteristics of the patient cohort
Characteristic Full cohort Without com
Number 89 77
Age, years 26.9 ± 5.3 26.8 ± 5.4
Male, % 96.6 96.1
Median ISS (IQR) 18 (11, 38) 18 (9, 34)
Median lactate (IQR) 1.8 (1.1, 2.9) 1.5 (1.1,2.5)
Mass transfusion, % 37.1 31.2
RRT, % 6.7 0
Mortality, % 10.1 0
Combined endpoint, % 13.5 -
Data are expressed as mean ± SD unless stated otherwise. *Combined endpoint is n
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injury (range 1–8 days). Nine patients (10.1 %) died. Me-
dian hospital day of death was 4 (3, 13) and ranged from
2 to 38. Of the six patients who required RRT, three (50
%) died. Urine samples were drawn at an average of
19.7 ± 10.8 hours after injury. At the time that urine
samples were drawn, 18.0 % of patients (n = 16) had AKI
by the Kidney Disease Improving Global Outcomes
(KDIGO) [4] criteria. The majority of patients (14.6 %)
were KDIGO stage 1 with 2.3 % and 1.1 % having
KDIGO stages 2 and 3, respectively. A further 17 pa-
tients developed AKI after urine sampling, resulting in
an overall rate of AKI of 37.1 %. KDIGO stages 1
through 3 occurred in 25.8 %, 4.5 % and 6.7 % of pa-
tients, respectively. The overall rates of AKI in this co-
hort have previously been described [5]. This should be
understood in the context of the limitations of the cur-
rently used standard for the diagnosis of AKI, serum
creatinine, given that resuscitation may affect these
classifications [6].
The median (IQR) of cystatin C (CyC) for those who
developed versus those who did not develop the out-
come were 12.95 ng/mg creatinine (1.24, 32.61) and 0.38
ng/mg creatinine (0.24, 0.87), respectively (p <0.001).
Median (IQR) of IL-18 was 5.34 pg/mg creatinine (0.26,
17.50) for patients with the primary outcome and 0.69
pg/mg creatinine (0.23, 1.64) for those without (p =
0.04). For KIM-1, there was no difference between those
with and without the outcome, 8.19 pg/mg creatinine
(5.38, 27.26) and 12.84 pg/mg creatinine (5.22, 25.29),
respectively (p = 0.59). The median values for LFABP
were higher in those who developed the composite out-
come, 3.35 ng/mg creatinine (0.89, 25.06), versus 0.20
ng/mg creatinine (0.06, 0.69), p <0.001. Finally, NGAL
was also significantly higher in those who had the out-
come compared to those that did not, 4.05 ng/m creatin-
ine g (0.41, 41.06) and 0.11 ng/mg creatinine (0.04,
0.34), respectively, p <0.001. There were no significant
differences noted between patients who required RRT bybined endpoint* Combined endpoint* P value
12 -
27.8 ± 4.9 0.57
100 1.0






eed for RRT or death. ISS injury severity score, RRT renal replacement therapy
Table 2 Univariate and injury severity score-adjusted models for
the combined outcome
Marker Univariate Adjusted for ISS
OR (95 % CI) P value AUC OR (95 % CI) P value
CyC 2.19 (1.48, 3.26) <0.001 0.815 1.97 (1.26, 3.10) 0.003
IL-18 1.68 (1.13, 2.49) 0.01 0.682 1.45 (0.96, 2.20) 0.08
KIM-1 0.85 (0.50, 1.44) 0.54 0.549 0.61 (0.31, 1.18) 0.14
LFABP 2.13 (1.41, 3.22) <0.001 0.842 1.92 (1.24, 2.99) 0.004
NGAL 1.96 (1.37, 2.81) <0.001 0.820 1.80 (1.21, 2.66) 0.004
ISS 1.05 (1.02, 1.08) 0.002 0.790 - -
Odds ratio (OR) represents per one log increase in biomarker-to-creatinine ratio
and one unit increase in injury severity score. CyC cystatin C, IL-18 interleukin-18,
KIM-1, kidney injury molecule-1, L-FABP liver-type fatty acid-binding protein, NGAL
neutrophil gelatinase-associated lipocalin, ISS, injury severity score
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who required RRT later in their hospital course. Figure 2
demonstrates the log-transformed values of the UBs
stratified by the presence or absence of the combined
outcome. Additional file 1 demonstrates the non-log-
transformed UB to creatinine ratios.
We examined the relations between the UB to creatin-
ine ratios and the composite endpoint in logistic regres-
sion models by examining both the UB to creatinine
ratio (Additional file 2) and the log of the UB to creatin-
ine ratio (Table 2). While both methods arrive at the
same AUCs (given inherent rank ordering), the logged
values better described the relationship. The ROCs for
each of the biomarkers that were statistically significant
are presented in Fig. 3. The AUCs for CyC, IL-18,
LFABP and NGAL were 0.815, 0.682, 0.842 and 0.820,
respectively. Table 2 shows both the unadjusted and ISS
adjusted logistic regression models. After adjustment,
Cyc C (odds ratio (OR) 1.97, 95 % CI 1.26, 3.10; p =
0.003), LFABP (OR 1.92, 95 % CI 1.24, 2.99; p = 0.004)
and NGAL (OR 1.80, 95 % CI 1.21, 2.66; p = 0.004)
remained significant. IL-18 (OR 1.45, 95 % CI 0.96, 2.20;
p = 0.08) was not significant after adjustment. Additional
file 3 reports these same models using the log mean bio-
marker levels not corrected for creatinine. These results
are similar with two exceptions. First, IL-18 was not sig-
nificant in the univariate model. Second, in the multi-
variate model, increasing KIM-1 concentrations were
associated with a decrease in the combined endpoint.
We also examined more traditional markers of AKI,Fig. 2 Distribution of log-transformed urinary biomarker values stratified by
represent the median (middle line) and interquartile range and diamonds re
values. CyC cystatin C, IL-18 interleukin-18, KIM-1: kidney injury molecule-1, L
gelatinase-associated lipocalinincluding creatinine and the average of the first 2 hours
of urine output. Both creatinine (OR 55.99, 95 % CI
4.59, 682.57; p = 0.002) and urine output (OR 1.04, 95 %
CI 1.01, 1.07; p = 0.02) were significant for the composite
outcome. While creatinine had a very high odds ratio, it
is important to note the wide confidence intervals.
Therefore this result should be interpreted with caution.
The pre-specified criteria for cutoff were satisfied by
all biomarkers except KIM-1, which met criteria for sen-
sitivity at a cutoff of 0.115. All other possible cutoff
values for KIM-1 failed to meet any of the three criteria
above. Optimal discriminative values for CyC, IL-18,
KIM-1, LFABP, NGAL and ISS were 2.24 ng/mg creatin-
ine, 2.21 pg/mg creatinine, 31.1 pg/mg creatinine, 1.76 ng/
mg creatinine, 1.51 ng/mg creatinine, and 27, respectively.the presence or absence of death or renal replacement therapy. Boxes
present the mean. The error bars indicate the maximum and minimum
-FABP liver-type fatty acid-binding protein, NGAL neutrophil
Fig. 3 Receiver operator characteristics curve for urinary biomarkers for the combined outcome. ROC receiver operator characteristic, CyC cystatin
C, LFABP L-type fatty acid-binding protein, NGAL neutrophil gelatinase-associated lipocalin
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negative predictive values at these cutoffs are presented in
Table 3. With the exception of KIM-1, UBs demonstrated
reasonable sensitivity (0.5 − 0.67) and specificity (0.79 −
0.91) for predicting the combined outcome.
Discussion
We found that UBs drawn at admission predicted the
subsequent need for RRT, and death. In the case of CyC,
LFABP and NGAL, the relationship remained significant
after adjustment for injury severity. As a stand-alonetest, NGAL with a cutoff of 1.51 ng/mg creatinine had a
positive predictive value of 53 % and a negative predict-
ive value of 95 %. This information also suggests that
UBs might improve the predictive capability of com-
monly used trauma scoring systems. In the military set-
ting, this information could be used to triage patients
and assign prioritization for aeromedical evacuation.
Prior work has also shown the ability of UBs to predict
both mortality and the need for RRT. Urinary NGAL is
perhaps the best studied. A pooled meta-analysis in 2009
that examined the diagnostic characteristics of urinary
Table 3 Sensitivity, specificity, negative predictive value and positive predictive value at optimal test characteristics
Marker Optimal discriminant value* Sensitivity Specificity Positive predictive value Negative predictive value
CyC 2.24 ng/mg 0.67 0.84 40 % 94 %
IL-18 2.21 pg/mg 0.67 0.79 33 % 94 %
KIM-1 31.1 pg/mg 0.75 0.14 12 % 78 %
LFABP 1.76 ng/mg 0.50 0.83 32 % 91 %
NGAL 1.51 ng/mg 0.67 0.91 53 % 95 %
ISS 27 0.75 0.65 25 % 94 %
*Units are expressed in ng/mg creatinine or pg/mg creatinine. CyC cystatin C, IL-18 interleukin-18, KIM-1 kidney injury molecule-1, L-FABP liver-type fatty acid-binding
protein, NGAL neutrophil gelatinase-associated lipocalin, ISS injury severity score
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0.782 and 0.706, respectively. Since the publication of this
analysis, further evidence has been published supporting
the association of NGAL with subsequent need for RRT
or with death. In a mixed ICU cohort of 529 patients,
NGAL was found to have sensitivity, specificity, positive
predictive value and negative predictive value of 0.47, 0.78,
0.20 and 0.94, respectively for the outcome of mortality in
7 days [7]. Test characteristics for the outcome of RRT
within 7 days were 0.64, 0.76, 0.07 and 0.99, respectively
[7]. Another large ICU cohort of 632 patients found that
NGAL had AUCs of 0.89 and 0.64 for the outcome of
RRT and mortality, respectively. These numbers are
broadly comparable to what we found in our smaller co-
hort, implying that the information is generalizable. Fur-
ther evidence also supports the association between
elevated NGAL levels and the subsequent need for RRT,
or death [8, 9]. Importantly, in one ICU cohort, the associ-
ation between NGAL levels and the combined endpoint
was significant after adjustment for age, acute physiology
and chronic health evaluation (APACHE) II scores, pres-
ence of organ failure, serum creatinine, sepsis and ICU lo-
cation [9]. Similarly, in patients undergoing cardiac
surgery, a dose response between quintiles of urinary
NGAL and the need for RRT was observed, again after ad-
justment for patient factors [10]. An association of other
biomarkers, including IL-18 [7, 9, 10] and CyC [7, 11, 12]
with death and RRT has also been observed. The evidence
for KIM-1 is conflicting, with one study demonstrating an
association with death and RRT [13] and another study
failing to demonstrate an association [7]. As KIM-1 appear
to peak later than other UBs (approximately 48 hours
[14]), it is possible that differences in timing of urine sam-
pling explains this variation. Notably, we only included pa-
tients who were admitted within 48 hours of injury, which
might explain why we failed to observe an association be-
tween KIM-1 and the combined outcome.
There is evidence that elevated UBs even in the ab-
sence of overt AKI [15, 16] or after adjustment for AKI
[9] increases the risk of mortality. This association is
biologically plausible by two possible mechanisms. First,
the kidneys receive approximately 20 % of cardiac output[17] and are sensitive to ischemic injury. Ischemia in the
kidney, reflected by an increase of UBs, may therefore be
indicative of global ischemia. Another possibility is that
AKI itself may contribute to death. Post trauma, AKI
has been demonstrated to significantly modulate pro-
and anti-inflammatory cytokines [18]. These changes in
the immune system are thought to be vital in organ-
organ interactions, which may result in failure of other
organs [19]. Retrospective work in the trauma popula-
tion showing that AKI is a stronger predictor of multi-
organ failure and death than hepatic, cardiac or
pulmonary dysfunction confirms this possibility [20].
During combat operations in Iraq and Afghanistan
over the past decade, rapid evacuation of injured pa-
tients out of theater, where RRT was not routinely un-
available, was essential for the care of injured service
members with life-threatening AKI [21]. However, in the
future rapid evacuation may be hampered by geograph-
ical challenges or prolonged transport times from point
of injury to definitive care facilities. The ability to iden-
tify patients at high risk, in order to prioritize evacu-
ation, is therefore highly desirable. Our work shows that
UBs can identify patients with combat injury who are at
high risk of requiring RRT or dying. The high negative
predictive value, albeit at some expense to the positive
predictive value, is of particular clinical significance to
military physicians. In a combat setting, it would be
preferable to evacuate a casualty who did not subse-
quently develop a significant complication than to not
evacuate one that did, because the latter would require a
large amount of resources, which are limited commod-
ities in the deployed setting. A strategy that involves UB
measurement at admission and triage to rapid evacu-
ation could save vital resources, conserving supplies and
enabling military physicians to care for a larger number
of casualties.
This work might also aid in the further development
of mortality risk scores in the civilian setting. Commonly
used scores for risk prediction after trauma include ISS
and the RTS [2]. Our work suggests that the addition of
UBs to these models may improve adverse event predic-
tion, including mortality and the need for RRT. There is
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prediction of mortality in patients with burns or trau-
matic injury. A study of 31 trauma patients admitted to
an ICU found correlation with NGAL levels and subse-
quent AKI, but did not examine the outcomes of mortal-
ity or need for RRT [22]. In another study of 90 patients
with burn injury (with total body surface area burn >20
%), urinary NGAL obtained shortly after admission was
found to be associated with both early (<3 days) and late
(>3 days) mortality [23]. Of note, elevated NGAL pre-
dicted mortality even after adjustment for age, TBSA, in-
halation injury and serum creatinine. Taken in the
context of our study, UBs drawn at admission may im-
prove risk prediction models in trauma patients. Future
work will be required to examine this hypothesis. A
priori stratification by age and co-morbid conditions
should be considered for future trials.
Our study has several limitations. We had initially
sought to enroll 226 subjects; however, the study took
place during a drawdown of combat forces in Afghanistan
which decreased enrollment. The smaller number (89)
limits the statistical power of the study and necessitated
the use of a combined outcome based on both death and
the need for RRT. Second, it was not possible to prospect-
ively collect all of the data and some variables had to be
examined retrospectively. Last, we do not have data on
long-term outcomes for these patients. Indeed, there are a
paucity of long-term follow up data on patients with com-
bat injury. However, UBs may have the ability to predict
long-term mortality [24]. Future studies should examine
the hypothesis that UBs predict long-term outcomes inde-
pendent of injury severity. These limitations should be
considered in the context in which the study was con-
ducted - a resource-poor combat environment. Indeed,
in the history of the wars in Iraq and Afghanistan, this
is the only work to successfully obtain urine samples
for analysis.
Conclusions
In conclusion, UBs are associated with the combined
outcome of death or need for RRT in combat casualties.
While this work is preliminary, UBs may have a role for
risk prediction in the setting of traumatic injury. Larger
multicenter studies will be required to determine how
UBs can best be used in future prediction models.
Key messages
 Urinary biomarker levels drawn at ICU admission
predict a combined endpoint of death or renal
replacement therapy in combat casualties.
 The relationship between the combined endpoint
and three of the urinary biomarkers studied, cystatin
C, L-type fatty acid-binding protein and neutrophilgelatinase-associated lipocalin, remained significant
even after adjustment for injury severity.
 Urinary biomarkers may provide additional
information to existing trauma severity scores to
improve risk prediction.
 In a combat or otherwise limited resource setting,
this information could be used to prioritize patients
for evacuation.Additional files
Additional file 1: Figure shows distribution of non-log-transformed
urinary biomarker to creatinine ratios stratified by the presence or
absence of death or renal replacement therapy.
Additional file 2: Table shows univariate and injury severity score-
adjusted models for the combined outcome with urinary biomarker
levels corrected for creatinine.
Additional file 3: Table shows univariate and injury severity score-
adjusted models for the combined outcome with urinary biomarker
levels not corrected for creatinine.Abbreviations
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